Ticket Cost: $95 (includes 3 hour open bar, food, and DJ entertainment - a portion of the cost is tax deductible)
David Fajgenbaum, MD, MBA, MSc, is the co-founder and Executive Director of the Castleman Disease Collaborative Network (CDCN) and a Research Assistant Professor of Medicine at the University of Pennsylvania. He is also battling idiopathic multicentric Castleman disease (iMCD)--a rare and deadly illness where the immune system attacks and shuts down multiple vital organ systems--as a physician, researcher, entrepreneur, and patient. He became ill with iMCD in 2010 as a third year medical student, spent five months hospitalized, had his last rites read, and has had life threatening relapses requiring combination chemotherapy. David has dedicated his life to curing the disease trying to take him down and we want you to join the fight. Research done by the CDCN could affect thousands of lives. While the immediate goal of the CDCN is to cure Castleman disease, the ultimate goal for Dr. Fajgenbaum is to create a blueprint for how to accelerate rare disease research using the CDCN’s model.
Castleman disease is as common as ALS, affects individuals of all ages, and two of the three subtypes are more deadly than lymphoma because it is so poorly understood. Simply, it is the most-deadly, most-common disease that you've never heard of. Help us change that and join us to raise funds for research (over 90% of all funding goes directly to medical studies). Event Information:
Event Date: October 28th, 2016, 8:00-11:00pm EST
Ticket Cost: $95 (includes 3 hour open bar, food, and DJ entertainment; A portion of the cost is tax deductible)Thank you to the Event Committee:Chairman: Ryan DinsmoreMembers: Christina Buckley, Mark Butler, Sarah Demakos Butler, Charlie Clarke, Owen Dinsmore, Kristen Dinsmore, Kevin Englert, Pete Fisher, Simon Flynn, Liam Grubb, Dr. Patrick Looser, Allie Riggins, Manasa Tanuku
Dr. Fajgenbaum was recently named a member of Forbes Magazine's 2015 30 Under 30 list for Healthcare and awarded one of the top honors in the rare disease field, 2015 RARE Champion of Hope: Science by Global Genes. Members of the CDCN have been published in numerous medical journals, including Lancet Hematology.
Check out a recent article in Science magazine about David and the CDCN.